000132513 001__ 132513
000132513 005__ 20240229105020.0
000132513 0247_ $$2doi$$a10.1002/ijc.31167
000132513 0247_ $$2pmid$$apmid:29159804
000132513 0247_ $$2ISSN$$a0020-7136
000132513 0247_ $$2ISSN$$a1097-0215
000132513 0247_ $$2altmetric$$aaltmetric:29983792
000132513 037__ $$aDKFZ-2018-00200
000132513 041__ $$aeng
000132513 082__ $$a610
000132513 1001_ $$0P:(DE-He78)b12aaacaa142dabed85c6d84d00bf0fb$$aSchroeder, Lea$$b0$$eFirst author$$udkfz
000132513 245__ $$aAntibodies against human papillomaviruses as diagnostic and prognostic biomarker in patients with neck squamous cell carcinoma from unknown primary tumor.
000132513 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000132513 3367_ $$2DRIVER$$aarticle
000132513 3367_ $$2DataCite$$aOutput Types/Journal article
000132513 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521206044_30036
000132513 3367_ $$2BibTeX$$aARTICLE
000132513 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132513 3367_ $$00$$2EndNote$$aJournal Article
000132513 520__ $$aTreatment of patients with neck lymph node metastasis of squamous cell carcinoma (SCC) from unknown primary tumor (NSCCUP) is challenging due to the risk of missing occult tumors or inducing toxicity to unaffected sites. Human papillomavirus (HPV) is a promising biomarker given its causal link to oropharyngeal SCC and superior survival of patients with HPV-driven oropharyngeal SCC and NSCCUP. Identification of HPV-driven NSCCUP could focus diagnostic work-up and treatment on the oropharynx. For the first time, we assessed HPV antibodies and their prognostic value in NSCCUP patients. Antibodies against E6 and E7 (HPV16/18/31/33/35), E1 and E2 (HPV16/18) were assessed in 46 NSCCUP patients in sera collected at diagnosis, and in follow-up sera from five patients. In 28 patients, HPV tumor status was determined using molecular markers (HPV DNA, mRNA and cellular p16INK4a). Thirteen (28%) NSCCUP patients were HPV-seropositive for HPV16, 18, 31, or 33. Of eleven patients with HPV-driven NSCCUP, ten were HPV-seropositive, while all 17 patients with non-HPV-driven NSCCUP were HPV-seronegative, resulting in 91% sensitivity (95% CI: 59-100%) and 100% specificity (95% CI: 80-100%). HPV antibody levels decreased after curative treatment. Recurrence was associated with increasing levels in an individual case. HPV-seropositive patients had a better overall and progression-free survival with hazard ratios of 0.09 (95% CI: 0.01-0.42) and 0.03 (95% CI: 0.002-0.18), respectively. For the first time, seropositivity to HPV proteins is described in NSCCUP patients, and high sensitivity and specificity for HPV-driven NSCCUP are demonstrated. HPV seropositivity appears to be a reliable diagnostic and prognostic biomarker for patients with HPV-driven NSCCUP.
000132513 536__ $$0G:(DE-HGF)POF3-316$$a316 - Infections and cancer (POF3-316)$$cPOF3-316$$fPOF III$$x0
000132513 588__ $$aDataset connected to CrossRef, PubMed,
000132513 7001_ $$aWichmann, Gunnar$$b1
000132513 7001_ $$aWillner, Maria$$b2
000132513 7001_ $$0P:(DE-He78)8c4d3a946a1fcde2ded7e17651fd0ed7$$aMichel, Angelika$$b3$$udkfz
000132513 7001_ $$0P:(DE-He78)1042737c83ba70ec508bdd99f0096864$$aWiesenfarth, Manuel$$b4$$udkfz
000132513 7001_ $$aFlechtenmacher, Christa$$b5
000132513 7001_ $$aGradistanac, Tanja$$b6
000132513 7001_ $$0P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aPawlita, Michael$$b7$$udkfz
000132513 7001_ $$aDietz, Andreas$$b8
000132513 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b9$$udkfz
000132513 7001_ $$00000-0002-5010-5236$$aHolzinger, Dana$$b10$$eLast author
000132513 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31167$$gVol. 142, no. 7, p. 1361 - 1368$$n7$$p1361 - 1368$$tInternational journal of cancer$$v142$$x0020-7136$$y2018
000132513 909CO $$ooai:inrepo02.dkfz.de:132513$$pVDB
000132513 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b12aaacaa142dabed85c6d84d00bf0fb$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132513 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8c4d3a946a1fcde2ded7e17651fd0ed7$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132513 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1042737c83ba70ec508bdd99f0096864$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132513 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000132513 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000132513 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-5010-5236$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000132513 9131_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000132513 9141_ $$y2018
000132513 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132513 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132513 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132513 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132513 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000132513 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132513 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132513 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132513 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132513 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132513 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132513 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000132513 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lMolekulare Diagnostik Oncogener Infektionen$$x0
000132513 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000132513 980__ $$ajournal
000132513 980__ $$aVDB
000132513 980__ $$aI:(DE-He78)F020-20160331
000132513 980__ $$aI:(DE-He78)C060-20160331
000132513 980__ $$aUNRESTRICTED